Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

摘要: Since the efficacy of ipilimumab on nivolumab-resistant advanced melanoma is extremely low, additional supportive therapy for anti-PD-1 antibody therapy-resistant needed. Although several therapies that enhance antitumor immune response antibodies have already been reported, unexpected immune-related adverse events were detected at same time. In this report, we describe a patient with treated nivolumab followed by intensity-modulated radiotherapy, which might triggered bullous pemphigoid (BP). cases BP developing in antibody-treated patients shed light possible pathogenesis through M2 macrophages.